Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29337674 | 0.80 | MAP4K4 (0.49) | MAP4K4EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL6579300 | 0.78 | MAP4K4 (0.62) | MAP4K4JAK2JAK1JAK3GRM5 | |
| SCHEMBL31176754 | 0.78 | IMPDH2 (0.61) | MAP4K4IMPDH2IMPDH1EGFRERBB2 | |
| SCHEMBL29336702 | 0.77 | F10 (0.64) | — | |
| SCHEMBL30285529 | 0.74 | F10 (0.43) | — | |
| SCHEMBL29336775 | 0.73 | F10 (0.47) | — | |
| SCHEMBL29338391 | 0.73 | MAP4K4 (0.43) | MAP4K4EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL6577317 | 0.73 | MAP4K4 (0.56) | MAP4K4CHEK2GRM5CSNK1A1CSNK1D | |
| SCHEMBL6576370 | 0.71 | F10 (0.61) | MAP4K4JAK2JAK1JAK3GRM5 | |
| SCHEMBL6578539 | 0.71 | GRM5 (0.52) | MAP4K4JAK2JAK1JAK3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673137-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182736-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | SIONNA THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| EP-4396176-A1 | INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023034946-A1 | INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | MAP4K4 4447/4885IMPDH2 278/4885IMPDH1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.